Online citations, reference lists, and bibliographies.
← Back to Search

Bevacizumab 15mg/kg Plus Cisplatin-pemetrexed (CP) Triplet Versus CP Doublet In Malignant Pleural Mesothelioma (MPM): Results Of The IFCT-GFPC-0701 MAPS Randomized Phase 3 Trial.

G. Zalcman, J. Mazières, J. Margery, L. Greillier, C. Audigier-Valette, D. Moro-Sibilot, O. Molinier, R. Corre, I. Monnet, V. Gounant, H. Janicot, R. Gervais, C. Locher, B. Milleron, Q. Tran, M. Lebitasy, F. Morin, C. Creveuil, J. Parienti, A. Scherpereel, French Cooperative Thoracic Intergroup
Published 2015 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
7500 Background: MPM median overall survival (OS) did not exceed 13 months with pemetrexed-platinum doublet, with virtually no surviving patients at 5 years. Vascular endothelial growth factor is a potent mitogen for MPM cells. Methods: In this French multicenter randomized phase 3 trial, eligible patients had unresectable, histologically proved MPM, age < 76, no prior chemo, PS 0-2, no thrombosis, nor bleeding. Randomized patients (1:1) received pem 500 mg/m2, CDDP 75 mg/m2 at D1, with (arm B) or without bevacizumab (arm A), 15 mg/kg Q21D, for 6 cycles. Arm B non-progressive patients received bevacizumab maintenance therapy until progression or toxicity. Primary endpoint was OS. 445 patients were to be randomized, and 385 events observed, to show a significant OS improvement, with 80% statistical power, 5% a-risk. Results: From Feb. 2008 to Jan. 2014, 448 patients were included in 73 centers. Males: 75.4%, median age: 65.7 years (range 34.7-75.9), PS 0-1: 96.7%. The IDMC recommended a second interim anal...

This paper is referenced by
Comment offrir à tous un accès aux thérapeutiques innovantes
J. Cadranel (2015)
Integrated palliative care of respiratory disease
Stephen J. Bourke (2013)
Malignant Pleural Effusions and Mesothelioma
David Cooper (2019)
The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations.
S. Novello (2016)
New directions in mesothelioma treatment
Anna K. Nowak (2015)
Seltene thorakale Tumorentitäten
Armin Frille (2015)
Advances in treatment of mesothelioma
C. Maggioni (2016)
L’année 2015 à travers le regard du comité de rédaction du Bulletin du cancer
N. Magne (2016)
Integrated Palliative Care of Respiratory Disease
Stephen J. Bourke (2019)
Closing faucets: the role of anti-angiogenic therapies in malignant pleural diseases
D. Márquez-Medina (2015)
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?
G. Bronte (2016)
A link between the fibroblast growth factor axis and the miR‐16 family reveals potential new treatment combinations in mesothelioma
K. Schelch (2018)
Novel insights into the pathophysiology and treatment of malignant pleural mesothelioma
Alistair M. Cook (2015)
A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors.
J. Soria (2016)
Malignant pleural mesothelioma: an update on diagnosis and treatment options
Sanjana Kondola (2016)
Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma
Licun Wu (2016)
Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma
Laurent Greillier (2016)
Systemic Approach to Malignant Pleural Mesothelioma: What News of Chemotherapy, Targeted Agents and Immunotherapy?
D. Signorelli (2016)
HMGB-1 Release and the CD8+ T Cell Response Elicited by Radiation Treatment in Malignant Pleural Mesothelioma
Matthew Wu (2015)
Inhibitors of Vascular Endothelial Growth Factor Receptor
Philip A. Harris (2017)
British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma
I. Woolhouse (2018)
Mésothéliomes pleuraux malins
Arnaud Scherpereel (2015)
Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)
Christine Raynaud (2015)
Extrapleural pneumonectomy for malignant pleural mesothelioma: is this an operation that should now be consigned to history?
Tom Treasure (2015)
Introducing the new BTS guideline: the investigation and management of pleural malignant mesothelioma
I. Woolhouse (2018)
A Randomized Phase II Study Adding Axitinib to Pemetrexed‐Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single‐Center Trial Combining Clinical and Translational Outcomes
Wieneke A. Buikhuisen (2016)
Semantic Scholar Logo Some data provided by SemanticScholar